Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 601–700 of 1,000
Beniwal-Patel, P. M., Samaan, S., Abreu, M. T., Deepak, P., & Yarur, A. J. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izag151 · Cited by 2
Ayoub, M., Tsutsumi, T., & Rinella, M. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70921 · Cited by 2
Self-citationYounossi, Z. M., Papatheodoridis, G., Tsochatzis, E. A., Buti, M., Rimassa, L., Pinzani, M., Lleò, A., Shawcross, D. L., Tacke, F., Wong, V. W., et al. (2026) · Liver International · doi:10.1111/liv.70806 · Cited by 2
Self-citationThe GLP ‐1–Mitochondria Axis in Metabolic Aging
Chang, R., Tsai, A. P., Wang, B., & Li, C. (2026) · Aging Cell · doi:10.1111/acel.70676 · Cited by 1
“Clinical improvement in an individual age-associated disease—for example, a reduction in major adverse cardiovascular events or histological improvement in MASH—demonstrates disease-specific efficacy but does not, by itself, demonstrate modification of biological aging.”
InfluentialToshikuni, N. (2026) · Metabolites · doi:10.3390/metabo16080586 · Cited by 1
Theocharidou, E., Arvanitakis, K., Koufakis, T., Tsochatzis, E. A., Francque, S., & Germanidis, G. S. (2026) · Drugs · doi:10.1007/s40265-026-02362-6 · Cited by 1
Eun, J. W., Cheong, J. Y., & Kim, S. S. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0074 · Cited by 1
Oh, J. H. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0062 · Cited by 1
Leke, R., Tan, J. Y., Ling, S., Siddiqui, M., Kakol‐Palm, D., Lindblom, A., Andréasson, A., Pellegrini, G., Söderberg, M. P., Zuydam, N. V., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101866 · Cited by 2
MRI in MASLD: technical foundations and guideline-based applications
Pu, J., Zhu, L., Wu, Y., Ping, F., Xu, J., Zhou, K., Wang, X., & Pan, J. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002471 · Cited by 2
Nakajima, A., Okanoue, T., Hiasa, Y., Takahashi, H., Opuni, K., Kosaka, N., Nishida, T., & Sanyal, A. J. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02507-0 · Cited by 1
Self-citationYou, Z., Yang, L., Long, Y., You, D., & Zhao, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815576 · Cited by 1
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Newsome, P. N., & Ajaz, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70143 · Cited by 2
“The trial will continue for a total of 240 weeks to determine whether inflammation and scarring improvements seen after 72 weeks translate into decreases in death, liver transplant, and other liver-related events [38].”
Self-citationSztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests
Messer, E. K., Petroff, D., Sugimoto, K., Newsome, P. N., Moriyasu, F., Shalimar, Burgio, M. D., Voican, C. S., Vilgrain, V., de Lédinghen, V., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101996 · Cited by 1
Self-citationScheiner, B., Dekervel, J., Piscaglia, F., Vitale, A., Kondili, L. A., Procopeț, B., Lazarus, J. V., Buti, M., Zelber‐Sagi, S., & Pinter, M. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101837 · Cited by 1
“72 More recently, emerging treatments for MASH and primary sclerosing cholangitis achieved higher fibrosis improvement rates on histology compared with their respective placebo control arms, 74,75 but their long-term effects are yet unknown.”
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
Gee, M. F. W., Billin, A. N., Chalfin, D. B., Fonstad, R. K., Devol, E. B., Feld, J. J., Patel, K., & Sanyal, A. J. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102041 · Cited by 1
Self-citationSchechter, M., Sehtman-Shachar, D. R., Fishkin, A., Mosenzon, O., Cukierman‐Yaffe, T., Sharon, R., Leibowitz, G., Arkadir, D., & Aharon‐Hananel, G. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70315 · Cited by 1
Pugliese, N., Polverini, D., Bertazzoni, A., Cerini, F., Pennisi, G., Lombardi, R., Gullace, V., Nicola, S. D., Masetti, C., Paviglianiti, A., et al. (2026) · Liver International · doi:10.1111/liv.70882 · Cited by 1
The hepatic sinusoid as a regulatory niche: From cellular specialization to precision hepatology
Fernández‐Iglesias, A., Harris, E. N., Jalan‐Sakrikar, N., Kaur, S., Zapotoczny, B., Ikejima, K., & Gracia‐Sancho, J. (2026) · Hepatology · doi:10.1097/hep.0000000000001870 · Cited by 1
Thorne, A. K., Waldeck, N. J., Rose, J. P., Stachowski, M. J., Guak, H., Keeble, A. R., Kuusik, B., Simon, E., Marcheva, B., Mastroni, J. V., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2618845123 · Cited by 1
Gastaldelli, A., Choi, E., Conde‐Knape, K., Göransson, O., Krook, A., Lehtonen, S. H., Roden, M., Schrauwen, P., Sparks, L. M., & Heni, M. (2026) · Diabetologia · doi:10.1007/s00125-026-06853-9 · Cited by 3
Self-citationDavies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Koning, M., Kovynev, A., Fondevila, M. F., Ruhé, E. J. M., Mommersteeg, M. C., Ramakers, C. R. B., Hutten, B. A., Verwer, B. J., Vlug, M. S., Kuiper, T., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01643-4 · Cited by 1
GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps
Werner, N., Pitchika, V., Bumm, C. V., Heck, K., Folwaczny, M., & Schwendicke, F. (2026) · Journal of Dental Research · doi:10.1177/00220345261488338 · Cited by 1
Xue, F., Liu, J., Chen, J., Li, X., 王思奎, Luo, Y., Zhang, B., Geng, J., Wang, W., Zhao, R., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00243-8 · Cited by 1
Pagès, L., Martí‐Carretero, A., Rojo, D., Sabiote, C., Faninam, F., Parks, S. C., Martínez-Gómez, M., Cusidó, M. S., Akhlaghi, N., Muñoz, S., et al. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00692-9 · Cited by 1
“…that tackling insulin-resistance and obesity-related pathways, MASLD/MASH pathomecanisms can be averted in early phases and potentially reverted when MASH and/or fibrosis are already established, which has already been proven in phase II trials [21, 24] and some ongoing phase III [25] (Fig.”
InfluentialDapagliflozin and metabolic dysfunction-associated steatohepatitis
Haddad, L., & Marciano, S. (2025) · BMJ · doi:10.1136/bmj.r1101 · Cited by 1
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf420 · Cited by 1
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Noureddin, M., Shringarpure, R., & Yale, K. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510444 · Cited by 1
Kemas, A. M. (2025) · doi:10.69622/29921738 · Cited by 1
Novère, N. G. L., Fettem, S., Boissel, M., Ning, L., Raverdy, V., Afnouch, M., Amanzougarene, S., Derhourhi, M., Toussaint, B., Vaillant, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681581 · Cited by 1
Optimal strategies to prevent disease progression and clinical events in MASLD
Rowe, I. A. C. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.11.013 · Cited by 2
Hoegeman, K. M., Wotring, J. W., Fursmidt, R. M., Gaetz, J., Khalil, E. M., Selinger, D. W., Kovalenko, I., Schultz, T. L., McCarty, S. M., O’Meara, M. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693988 · Cited by 2
“72 DPP-IV is a key enzyme that degrades endogenous GLP-1, so its inhibition is expected to increase levels of active GLP-1.”
Khokhar, M., Yadav, D., & Sharma, P. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01417-5 · Cited by 1
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Maqsood, A., Khan, A. R., Aaqil, S. I., Cheema, A. A. A., Ali, M., Jacob, J., Muhammad, N., & Siddiqi, A. K. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005191 · Cited by 2
Lebeaupin, C., Donahue, K. L., Lal, S., Christensen, S. M., Asano, S., Wadsworth, M. H., Bound, K., De, S., McMahon, J., Schlerman, F., et al. (2025) · bioRxiv (preprint) · doi:10.64898/2025.12.17.694415
MASLD and MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint
van Kleef, L. A., Pustjens, J., & Brouwer, W. P. (2025) · Liver International · doi:10.1111/liv.70161 · Cited by 1
Epidemiology and risk factors of hepatocellular carcinoma
González, A. F., & Mauro, E. (2025) · Revisiones en cáncer · doi:10.20960/revcancer.00111
Guerci, B., Joubert, M., Riachi, G., Antoine, M.-L., Clabaut, D., Fay, R., & Prévost, G. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101679
The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered
Ho, C.-T., Kao, W., & Su, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001266
Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience
Siderova, M. V., Shopov, G., Kehayova, G. K., & Dragomanova, S. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e163319
Incretin integration: Charting the future of cardiovascular-kidney-metabolic health
Wang, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001277
Prevention of Antipsychotic-Induced Weight Gain: Beyond Metformin
Iruzubieta, P., & Crespo, J. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf123
The Ceiling Is Real: MASH Needs Combination, Not Celebration
Kumar, A., Sharma, P., & Arora, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103147
Author Reply to The semaglutide paradox in non-overweight diabetes: a benefit without explanation
Kishimori, T., & Kato, T. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf090
de Souza, M. H. G., Al‐Sharif, L., Khalil, S. M., & Diaz, I. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103173
MASLD: Mit GLP-1-Rezeptoragonisten an die Fettleber
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5160-x
新井泰央 (2025) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.21.216
Lega, S. (2025) · Medico e Bambino · doi:10.53126/meb44419
(2025) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-025-1599-6
(2025) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-025-1595-x
Cinque, F., Fracanzani, A. L., & Lombardi, R. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.08.006
Mutchmore, A., Grbic, D., Cauchon, M., Plourde, M.-É., & Lanthier, L. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.08.009
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
Hollander, P. A. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2559539
Metabolic dysfunction-associated steatotic liver disease and diabetes: Together against the heart
de Souza, M. H. G., Nogueira, P. M. M., & Villela‐Nogueira, C. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i9.109737 · Cited by 2
2025 Clinical Practice Guidelines for Diabetes: Pharmacological Treatment of Type 2 Diabetes
Choi, J. H. (2025) · Journal of Korean Diabetes · doi:10.4093/jkd.2025.26.3.158
Interdisziplinäre Strategien zur Prävention und Therapie der MASLD
Roehlen, N., Laubner, K., Seufert, J., & Thimme, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2532-5919
Pharmacologic Confounders in Steatotic Liver Disease Outcomes Research—Reply
Ochoa‐Allemant, P., Hubbard, R. A., & Serper, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.5043
Gastrointestinal hormone receptor agonists: Time for gastroenterologists to lead, not to hesitate
Gasbarrini, A., & Gasbarrini, G. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.08.093
Verlaan, J. P. L., van Es, N., & Scheres, L. J. J. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.035
Fennel, Z. J., Kurian, A., Bourrant, P., Skiles, C. M., Castro, R. J., Yee, E. M., Greilach, S. A., Keirstead, H. S., Nistor, G., Berchtold, N. C., et al. (2025) · Obesity · doi:10.1002/oby.70068 · Cited by 1
Ballesteros, E. J. G., Araujo, J. E. G., Acero, D. A. W., Quezada, J. U. C., Garcia, M., Florez, Á. H. S., Andino, M. N. H., & Ibarra, A. C. R. (2025) · IECCMEXICO · doi:10.64784/010
Thrombospondin-2: a promising but unproven biomarker for MASH
Castéra, L. (2025) · Gut · doi:10.1136/gutjnl-2025-337225
Identifying and managing liver disease in primary care
Jarvis, H. (2025) · BMJ · doi:10.1136/bmj.r2332
Yoshigi, M., Kamdem, S. D., Wang, H., Khambete, A., Sprouse, F., Kameni, E. M., Atiogue, E., Pellizzari, S., Evason, K. J., Helms, M. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.19.688968
Chang, J. Y., & Lee, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70401
Stuby, J., & Blümel, S. (2025) · Schweizer Gastroenterologie · doi:10.1007/s43472-025-00183-8
Metabolisch assoziierte Fettlebererkrankung (MASLD)
Kreimeyer, H., Gerken, G., & Canbay, A. E. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21164-5.00027-1
Guo, S., Li, Z., Han, Z., Ge, Y., Shi, H., Zheng, Y., Tan, W., Cheng, X., Li, Z., Yao, L., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s546860
“6 9 This underscores the promising therapeutic potential of strategies that modulate intrahepatic inflammation or combine metabolic and immune targets.”
Trifylli, E.-M., Charalambous, C. H., Spiliotopoulos, N., Papadopoulos, N., Oikonomou, A., Manolakopoulos, S., & Deutsch, M. J. (2025) · Livers · doi:10.3390/livers5040065
“…agents and insulin sensitizers: Metformin [96], thiazolidine-diones (e.g., pioglitazone) [97], GLP-1 receptor agonists (e.g., semaglutide) [98], which have been proved beneficial for insulin sensitivity enhancement, as well as for hepatic steatosis reduction, with the latter being…”
Owusu, N., Kalutkiewicz, K. J., Li, J., Allen, A. M., Loomba, R., Ehman, R. L., & Yin, M. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.1267
Wang, M., Jiang, Y.-N., Li, P., & Wu, Y.-J. (2025) · Systematic Reviews · doi:10.1186/s13643-025-03011-x · Cited by 1
Obesity Pharmacotherapy: A Practical Approach to Patient-Centered Medication Selection
Park, J. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.4.194 · Cited by 1
Adipose Tissue Systems Biology and Metabolic Disease
Tavanez, A. R. (2025) · University of Southern Denmark Research Portal (University of Southern Denmark) · doi:10.21996/dcf84569-a323-4949-832a-e4b1806d4cbc
Schenker, R. B., Fomenko, K., Mitsinikos, F. T., & Vidmar, A. P. (2025) · JPGN Reports · doi:10.1002/jpr3.70131
Abdu, E., Alghamdi, R., Mohsen, A., Alabbad, Z. M., Kharabah, M. A., Al-Thagfi, A., Al-Shabeeb, M., Alanzi, F. M., Al-Harthi, H., Alessa, A., et al. (2025) · medRxiv · doi:10.64898/2025.12.22.25342824
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8383 · Cited by 3
Self-citationSaad, A. B., Arghiani, N., Weilheimer, A., Gentile, S. D., Toles, B. J., Tripathi, S., Sayed, S. M., Chandraker, A. K., & Mullen, A. C. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001022
“[8] A better understanding of the pathogenesis and progression of MASLD is still needed to identify more effective therapies.”
Ciudin, A., & McGowan, B. M. (2026) · Nature Medicine · doi:10.1038/s41591-025-04131-6
Bhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Onaga, R., Taharabaru, T., Higa, Y., Higashi, T., & Motoyama, K. (2026) · Research Square · doi:10.21203/rs.3.rs-8527688/v1
Song, S. J., Wong, V. W., & Yip, T. C. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.1459 · Cited by 1
Recombinant live biotherapeutics against chronic metabolic diseases: Challenges and opportunities
Swamy, P., Singh, L., Sehrawat, P., & Mahajan, D. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.008
Lassailly, G., Pattou, F., & Mathurin, P. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.006
MASH and the race for liver antifibrotics
Wills, Q. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2025.1704078 · Cited by 1
John, M., & Manoj, K. S. (2026) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_25_25
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
“…1197 adults with biopsy-confirmed non-cirrhotic MASH (fibrosis stages F1–F3), semaglutide 2.4 mg weekly achieved MASH resolution in 63% of participants versus 34% in the placebo group ( p 0.001), and ≥ 1-stage fibrosis improvement in 37% versus 22% ( p 0.001), respectively, after 72 weeks [34].”
InfluentialWan, K.-R., Qian, C., & Liu, L.-M. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i6.115232 · Cited by 1
Valcin, J. A., Millender-Swain, T., Paul, J. R., Collins, B. K., Ghandour, F., Diffalha, S. A., Pollock, J. S., Pollock, D. M., Ballinger, S. W., Gamble, K. L., et al. (2026) · Function · doi:10.1152/function.082.2025
“Livers were collected at ZT1, 5, 9, 13, 17, and 21, and total RNA was isolated from tissues using TRI-Reagent (Sigma-Aldrich, St. Louis, MO).”
merging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence
Madsbad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v14i1.7208
Tou, A. M., & Panganiban, J. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115011
Kow, C. S., Thiruchelvam, K., Hasan, S. S., & Zaihan, A. F. (2026) · Proceedings of Singapore Healthcare · doi:10.1177/20101058261424018
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.